The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) was awarded an $8.9 million grant from The US Department of Commerce’s National Institute of Standards and Technology for high-impact biopharmaceutical manufacturing projects to support the nation’s response to the COVID-19 pandemic. Congratulations to CBI Trainer and director of NIIMBL, Dr. Kelvin Lee, Gore Professor of Chemical and Biomolecular Engineering at the University of Delaware.
NIIMBL will use the $8.9 million CARES Act award to fund manufacturing projects at eligible institutions around the country that:
- Improve COVID-19 testing capabilities, including rapid in-house diagnostic systems.
- Identify reliable domestic supply chains for the production of respirators and personal protective equipment (PPE).
- Validate decontamination approaches for clinical spaces.
- Develop contact tracing technology for essential workers in pharmaceutical manufacturing facilities.
- Build flexible manufacturing capabilities that allow for the quick scale-up in production of biologic therapies and essential medical products.
Nine projects were chosen by NIIMBL to receive funding provided by the above grant. CLICK HERE to learn more about the projects.
CLICK HERE to read the announcement of the award on the NIST website
CLICK HERE to read UDaily article by Beth Miller announcing award of grant
